Kilambi News
Sunday, November 22, 2026

Bausch and Lomb eye pain drug misses Phase 2 goal

Life Sciences Sunday, November 22, 2026 - Updated Nov 22, 2026 07:05

Bausch and Lomb's BL1332 eye drop failed its Phase 2 primary endpoint in 129 patients after laser eye surgery, though pain scores favored the drug numerically.

Why it matters: A primary endpoint miss on a first in class pain mechanism leaves the programme dependent on regulatory talks, and the shares fell on the readout.

Data as of Company topline results reported November 19, 2026; figures from the company release as carried by Reuters and Benzinga.

Bausch and Lomb said on November 19 that BL1332, its experimental eye drop for pain after laser eye surgery, failed to meet the primary goal of a mid stage study. The Phase 2 trial enrolled 129 adults undergoing photorefractive keratectomy, a laser procedure to correct nearsightedness, and tested the drug against a vehicle drop.

The primary endpoint was a statistically significant improvement in the sum of pain intensity differences over the first 24 hours after surgery. Neither dose cleared it. The higher dose, 0.30 percent, recorded a least squares mean difference of minus 11.5 against vehicle, and the 0.15 percent dose minus 9.0, with negative values favoring BL1332. Pain relief was numerically greater across the 72 hour analysis, and at six hours the higher dose showed nominal significance on a secondary measure, with complete relief in 14.0 percent and 14.6 percent of patients on the two doses against 3.7 percent on vehicle.

BL1332 is a topical antagonist of TRPV1, a pain receptor, and Bausch and Lomb describes it as first in class. The company reported no treatment related or serious adverse events and no discontinuations, and said the treatment was well tolerated. It is completing its analysis and plans to discuss the findings, together with earlier Phase 1b challenge study data, with the Food and Drug Administration, including potential plans for a Phase 3 trial.

Shares fell about 5 percent in afternoon trading after the release, before recovering part of the loss. The miss is a pipeline setback rather than a franchise problem: Bausch and Lomb reported third quarter revenue of $1.375 billion in October and raised its full year guidance, so the investment case rests on whether regulators accept a redesigned late stage programme for a drug that relieved pain numerically but not significantly.

Sources

  1. Bausch + Lomb eye-drop drug misses mid-stage study main goal - Reuters via TradingView - 2026-11-19
  2. Bausch + Lomb post-surgery eye pain drug misses study goal but shows early relief - Benzinga via TradingView - 2026-11-20